Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20858676 | 0.78 | ACLY (0.34) | MAOATRPA1IDO1 | |
| SCHEMBL20858621 | 0.77 | CYP2A6 (0.38) | MAOAMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL26758909 | 0.77 | MAOA (0.37) | MAOAMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL18876064 | 0.74 | TRPA1 (0.38) | MAOAMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL16048413 | 0.74 | MAOA (0.35) | MAOAMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL25166132 | 0.74 | MAOA (0.35) | MAOAMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL1172783 | 0.74 | MAOA (0.35) | MAOAMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL18876037 | 0.74 | MAOA (0.35) | MAOAMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL29591293 | 0.72 | MAOA (0.46) | MAOAMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL4419988 | 0.72 | MAOA (0.46) | MAOAMAOBHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4257196-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | The University of Hong Kong (HK) | 2023-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | YEATS2, YEATS4, KNTC1 | MAOA 3382/4885MAOB 3827/4885HTR2A 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.